Cabaletta Bio Inc Stock

$1.56

2.63% yesterday

Nasdaq, Jul 01, 10:15 pm CET

ISIN

US12674W1099

Symbol

CABA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Cabaletta Bio Inc Stock price

$1.56

-9.72 86.17% 5Y

Nasdaq, Closing price Tue, Jul 01 2025

+0.04 2.63%

ISIN

US12674W1099

Symbol

CABA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$140.3m

Enterprise Value

$31.8m

Net debt

positive

Cash

$131.8m

Shares outstanding

50.7m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | 23.58

EV/Sales

- | 5.34

EV/FCF

negative

P/B

0.65

Financial Health

Equity Ratio

82.32%

Return on Equity

-76.06%

ROCE

-102.36%

ROIC

-614.68%

Debt/Equity

0.19

Financials (TTM | estimate)

Revenue

$0.0 | $6.0m

EBITDA

$-129.3m | $-165.0m

EBIT

$-134.2m

Net Income

$-126.8m | $-125.6m

Free Cash Flow

$-97.2m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

-53.45% | -37.13%

EBIT

-56.58%

Net Income

-64.90% | -8.38%

Free Cash Flow

-47.19%

Margin (TTM | estimate)

Gross

EBITDA

- | -2,773.26%

EBIT

Net

- | -2,110.38%

Free Cash Flow

EPS

$-2.49

FCF per Share

$-1.92

Short interest

7.32%

Employees

163.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,951 stocks worldwide.

Get Started for Free Today

Cabaletta Bio Inc Stock Analysis

Unlock Scores for Free

??

17 Analysts have issued a Cabaletta Bio Inc forecast:

14x Buy

82%

3x Hold

18%

More details on Analyst Estimates Including Price Targets

17 Analysts have issued a Cabaletta Bio Inc forecast:

Buy

82%

Hold

18%

Analyst Estimates with Stock Price Targets

Financial data from Cabaletta Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	30 30	44% 44% -
- Research and Development Expense	104 104	61% 61% -
EBITDA	-129 -129	53% 53% -
- Depreciation and Amortization	4.91 4.91	239% 239% -
EBIT (Operating Income) EBIT	-134 -134	57% 57% -
Net Profit	-127 -127	65% 65% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cabaletta Bio Inc Stock News

Neutral

GlobeNewsWire

●

21 days ago

Cabaletta Bio Announces Pricing of Public Offering of Securities

PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of i...

Neutral

Seeking Alpha

●

21 days ago

Cabaletta Bio: Sector Headwinds And Funding Issues

Cabaletta Bio's CAR T-cell therapy shows durable efficacy in autoimmune diseases, with manageable side effects and promising early clinical data updates. The company plans a BLA submission for myositis in 2027, supported by FDA's RMAT designation and a focused clinical trial strategy. Financial risk is significant: current cash plus a new offering extends runway only modestly, likely insufficie...

Neutral

GlobeNewsWire

●

21 days ago

Cabaletta Bio Announces Proposed Public Offering of Securities

PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accom...

More Cabaletta Bio Inc News

Company Profile

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Head office	United States
CEO	Steven Nichtberger
Employees	163
Founded	2017
Website	www.cabalettabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now